Takeda Pharmaceutical Company Limited (TAK) Discusses Zasocitinib Phase III Psoriasis Data and Commercial Strategy - Slideshow

Takeda Pharmaceutical presented Phase III clinical trial data for zasocitinib, an oral JAK inhibitor, demonstrating significant efficacy in moderate-to-severe plaque psoriasis during a March 2026 investor event. The slideshow highlighted zasocitinib’s superior performance over placebo in key endpoints, including PASI 75/90 response rates, positioning it as a potential first-line oral therapy for psoriasis patients. Commercial strategy details revealed plans for a 2026 U.S. launch, targeting dermatologists and leveraging Takeda’s existing immunology infrastructure to accelerate market adoption. Safety data emphasized a favorable risk-benefit profile, with adverse event rates comparable to existing JAK inhibitors, addressing prior regulatory concerns about class-wide cardiovascular risks. Analysts noted Takeda’s focus on differentiating zasocitinib through convenience (once-daily dosing) and pricing strategies to compete with injectable biologics like Humira and Cosentyx.